About this Research Topic
Herbal medicines continue to evolve in the daily lifestyle and treatment regimens of patients, with illnesses such as cancer. Herbal medicines have a significant effect on reducing fatigue and pain, improving respiratory tract infections and gastrointestinal problems including diarrhea, nausea, and vomiting, protecting liver function, and even ameliorating the symptoms of cachexia. Although herbal medicines have not been fully accepted by mainstream medicine because of the complex nature of the formulae, the stringent quality control of herbal medicines, such as that in Japan, and reproducibility of preclinical findings, together with few adverse events, have made herbal medicines more and more attractive for the management of intractable diseases and health problems.
Older individuals show a spectrum of features categorized as frailty, defined by unintentional weight loss, self-reported exhaustion, muscle weakness, slow walking speed, and low physical activity. The functional and behavioral aspects of frailty are associated with loss of lean mass in the form of sarcopenia. While middle-age is often associated with increased body weight in many developed countries, later life is frequently characterized by loss of body mass, loss of muscle mass and bone loss. Frailty is thus a big problem in aged societies which shorten the healthy life-span.
This review series summarize the current state and future direction of herbal medicines and frailty from translational points of view. The multi-component herbal medicines capable of targeting multiple sites could be useful for reducing polypharmacy in frailty. Mechanistic studies and identification of active compounds could lead to new discoveries in aging sciences and facilitate clinical application of herbal medicines in the world.
A. Herbal medicines- Introduction and Kampo recipes for frailty
B. Frailty- From molecular mechanisms to clinical diagnosis and complications
C. Herbal medicines and frailty- Experimental studies
D. Herbal medicines and frailty- Clinical studies
If submitting to Frontiers in Pharmacology (section Ethnopharmacology) , please note-
This specialty section focuses on biological and pharmacological activities of plants, fungi and other organisms used locally or traditionally as a medicine or to improve health. Studies with the specific aim to either improve local healthcare by developing products based on such knowledge or studies in the context of drug discovery / development from natural sources will be considered if they are based on biological resources with a clear and well-defined local or traditional use. Purely biodiversity-based screening studies and studies of established natural products and their mechanism of action are outside the scope of this section. Studies reporting such local and traditional uses will only be accepted if the comply with the ConSEFS standards (Heinrich et al. 2017 ) . Toxicological research and clinical studies on medicinal plants are welcome.
Manuscripts which are highly specific, lack breadth and often are very similar to previous papers (often by the same group) are not acceptable and this will be assessed.
The following basic guidelines, focused on best practice in ethnopharmacology, should be followed by all submissions:
- This Specialty Section of Frontiers in Pharmacology subscribes to the taxonomic standards laid down most importantly at the Kew MPNS portal (http://mpns.kew.org/mpns-portal/) and also the Royal Botanic Gardens/Kew/Missouri Botanical Garden `The Plant List` initiative (www.theplantlist.org). Of course, full botanical documentation is essential (i.e. a voucher specimen deposited in a recognized herbarium).
- Antioxidant activity: here in vivo or in vitro studies using generally accepted pharmacological models are essential. Simple in silico and pharmacologically irrelevant assays for antioxidant activity (e.g. the DPPH assay, FRAP (Ferric Reducing Ability of Plasma), ABTS (2,2'-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid)) are not acceptable as a main tool for assessing an extract or a compound for activity. Such assays are commonly used in food chemistry and other fields, but are not of pharmacological relevance.
- Dose ranges must be pharmacologically relevant. While impossible to define an exact cut-off, studies testing extracts at implausibly high doses are increasingly common in the literature.
- Positive and negative controls must be included.
- Models must be pharmacologically relevant and plausible - a complex question depending on the specific goals of the study. Authors must consider the ethical acceptability of further in vivo studies on an already well-studied species, demonstrating some common activity (e.g. an anti-inflammatory effect studied in the rat-paw oedema).
- The composition of the study material must be described in sufficient detail
- If ‘pure’ compounds are used information on the level of purity must be included
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.